NL-OMON24808已完成未知
CareMoreCTC study 1:Prognostic value of HER2-positive circulating tumor cells inmetastatic breast cancer patients treated with aromataseinhibitors (CareMore-AI study)
Erasmus MC Cancer InstituteDepartment of Medical Oncology0 个研究点目标入组 18 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 18
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational non invasive
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •Female patient with metastatic breast cancer
- •Age = 18 years
排除标准
- •Adjuvant chemotherapy within 6 months prior to treatment start
- •Other anticancer chemotherapy, use of biological response modifiers, or immunotherapy within two weeks prior to treatment start. Hormonal antitumor treatment within one week prior to treatment start.
研究者
相似试验
已完成
不适用
CareMore study 1: prognostic value of HER2-positive circulating tumor cells in metastatic breast cancer patients treated with aromatase inhibitors (CareMore-AI study)metastatic mammary cancer10006291Metastatic breast cancerNL-OMON47479Erasmus MC, Universitair Medisch Centrum Rotterdam300
已完成
不适用
Correlation between Prognosis and HER2 status in Advanced/Recurrent Gastric Cancer: Multicenter Retrospective AnalysisAdvanced/Recurrent Gastric CancerJPRN-UMIN000006451ational Cancer Center Hospital East300
已完成
不适用
Prognostic significance of HER2 expression in patients with resectable gastric cancerGastric adenocarcinomaCancerISRCTN54802594Inje University Busan Paik Hospital782
尚未招募
2 期
Clinical Trial of Eribulin in Combination with Anrotinib for HER-2 Negative Locally Advanced or Metastatic Breast CancerBreast CancerNCT06678230The First Hospital of Jilin University40
招募中
1 期
Phase I clinical study on the safety of HER2-specific chimeric antigen receptor (CAR) gene-modified T cell therapyHER2 positive osteosarcoma/soft tissue sarcoma and gynecologic malignancyJPRN-jRCT2033220088Yozo Nakazawa12